Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms
- PMID: 18457323
- DOI: 10.1002/cncr.23523
Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms
Abstract
Background: The behavior of neuroendocrine neoplasms is poorly defined, and predictors of outcome after surgical resection have yet to be identified. Consequently, guidelines for treatment remain unclear. Current pathologic classification systems do not permit meaningful discrimination of hepatic neuroendocrine neoplasms.
Methods: The authors reviewed prospectively maintained databases from 2 institutions of patients who underwent hepatic resection for neuroendocrine neoplasms between 1990 and 2006. Patient, tumor, and operative characteristics were analyzed to identify factors associated with overall survival, progression-free survival, and symptom control. Hepatic neoplasms were stratified by using a 3-tier pathologic classification system based on the number of mitotic figures and the presence of tumor necrosis that was recently validated for pancreatic neuroendocrine neoplasms.
Results: Seventy patients were identified from the databases. Low-grade, intermediate-grade, and high-grade neoplasms were identified in 53%, 37%, and 10% of patients, respectively. After a median follow-up of 51 months, the median overall survival for all patients was 91 months, and it was 108 months when 7 patients with high-grade neuroendocrine carcinomas were excluded. Progressive disease was eventually observed in 81% of patients, and the median progression-free survival was 17 months. The median time to the onset of symptoms was 39 months for patients who presented with hormonal symptoms and 80 months for all patients. Histologic grade was associated with poorer overall and progression-free survival.
Conclusions: When performed in a context of aggressive multimodality therapy, long-term outcomes after partial hepatectomy for hepatic neuroendocrine neoplasms were favorable; however, disease progression was eventually observed in the majority of patients. Several oncologic variables were associated with significant differences in survival after resection. A novel pathologic classification system appears to enhance prognostic stratification of patients with hepatic neuroendocrine neoplasms.
(Copyright) 2008 American Cancer Society.
Similar articles
-
Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach.Surgery. 2011 Feb;149(2):209-20. doi: 10.1016/j.surg.2010.06.008. Epub 2010 Aug 2. Surgery. 2011. PMID: 20674950
-
Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.J Hepatobiliary Pancreat Surg. 2009;16(3):359-66. doi: 10.1007/s00534-009-0069-7. Epub 2009 Mar 20. J Hepatobiliary Pancreat Surg. 2009. PMID: 19300896
-
Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis.J Am Coll Surg. 2007 Mar;204(3):372-82. doi: 10.1016/j.jamcollsurg.2006.12.019. J Am Coll Surg. 2007. PMID: 17324770
-
[Hepatic resection for hepatocellular carcinoma--results and analysis of the current literature].Zentralbl Chir. 2009 Apr;134(2):127-35. doi: 10.1055/s-0028-1098881. Epub 2009 Apr 20. Zentralbl Chir. 2009. PMID: 19382043 Review. German.
-
Predictive models in colorectal liver metastases--can we personalize treatment and outcome?Dig Surg. 2008;25(6):406-12. doi: 10.1159/000184731. Epub 2009 Feb 12. Dig Surg. 2008. PMID: 19212112 Review.
Cited by
-
Place of surgical resection in the treatment strategy of gastrointestinal neuroendocrine tumors.Target Oncol. 2012 Sep;7(3):153-9. doi: 10.1007/s11523-012-0230-0. Epub 2012 Aug 25. Target Oncol. 2012. PMID: 22923166 Review.
-
Analysis of the clinicopathological features and prognostic factors of primary hepatic neuroendocrine tumors.Oncol Lett. 2018 Jun;15(6):8604-8610. doi: 10.3892/ol.2018.8413. Epub 2018 Apr 2. Oncol Lett. 2018. PMID: 30065788 Free PMC article.
-
A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy.Case Rep Oncol. 2011 May;4(2):260-6. doi: 10.1159/000328802. Epub 2011 May 24. Case Rep Oncol. 2011. PMID: 21734880 Free PMC article.
-
Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy.BMC Cancer. 2010 Aug 23;10:448. doi: 10.1186/1471-2407-10-448. BMC Cancer. 2010. PMID: 20731845 Free PMC article.
-
Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.World J Gastroenterol. 2016 Dec 7;22(45):9944-9953. doi: 10.3748/wjg.v22.i45.9944. World J Gastroenterol. 2016. PMID: 28018101 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical